Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 283 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... February 3, 2025 EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab June 30, 2020 FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... June 6, 2023 Load more HOT NEWS Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... Immunotherapy before Surgery Appears Effective for Some with Melanoma This Harmful Chemical Is Still Being Used In Popular Household Products Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO...
